| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/29/2008 | WO2008008841A3 Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders |
| 05/29/2008 | WO2008008733A3 Nanoparticulate sorafenib formulations |
| 05/29/2008 | WO2008002641A3 Protein phosphatase inhibitors |
| 05/29/2008 | WO2007149283A3 Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| 05/29/2008 | WO2007145863A3 Sustained release formulation of naltrexone |
| 05/29/2008 | WO2007143423A3 Treatment of hot flashes using muscarinic receptor antagonists such as oxybutynin |
| 05/29/2008 | WO2007138301A3 Novel formulation |
| 05/29/2008 | WO2007136719A3 Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof |
| 05/29/2008 | WO2007134203A3 Anticancer treatments with a combination of docetaxel and ecteinascidin |
| 05/29/2008 | WO2007130353A3 Phase 2 inducers, ppar-alpha agonists and related signalling pathways protect cartilage against inflammation, apoptosis and stress |
| 05/29/2008 | WO2007118819A3 Novel crystalline compounds |
| 05/29/2008 | WO2007111998A3 Dsrna compositions and methods for treating hpv infection |
| 05/29/2008 | WO2007111983A3 New therapeutic combinations for the treatment or prevention of psychotic disorders |
| 05/29/2008 | WO2007106884A3 Methods of treating muscular wasting diseases using nf-kb activation inhibitors |
| 05/29/2008 | WO2007106503A3 Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| 05/29/2008 | WO2007103468A3 Use of vx-702 for treating rheumatoid arthritis |
| 05/29/2008 | WO2007084221A3 Methods and apparatus for identifying subject matter in view data |
| 05/29/2008 | WO2007078848A3 Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid |
| 05/29/2008 | WO2007075465A8 Dimers and adducts of 6-[(substituted) phenyl] triazolopyrimidines useful as anticancer agents |
| 05/29/2008 | WO2007074456A3 Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids |
| 05/29/2008 | WO2007072150A3 Piperidine derivatives |
| 05/29/2008 | WO2007071453A8 Organophosphoric derivatives useful as anti-parasitic agents |
| 05/29/2008 | WO2007054139A3 Styrylsulfonamides, their manufacture and use as pharmaceutical agents |
| 05/29/2008 | WO2007038669A9 Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors |
| 05/29/2008 | WO2007034210A8 Deglycosylated anti-muc-1 antibodies and uses thereof |
| 05/29/2008 | WO2007022076A9 Prevention of neurodegeneration by macrolide antibiotics |
| 05/29/2008 | US20080126195 Methods and Compositions for Treating Lactose Intolerance |
| 05/29/2008 | US20080125497 plant extracts comprising violaxanthinand isomers, beta-carotene, lycopene, alpha-cryptoxanthin, phytoene and phytofluene mixed with xanthophyll, used as foods or feed supplements |
| 05/29/2008 | US20080125496 Antimicrobial flavor and oral care composition containing the same |
| 05/29/2008 | US20080125495 Ameliorant For Renal Insufficiency |
| 05/29/2008 | US20080125494 an aqueous solution comprising primary, secondary or tertiary alkylamines and nonionic surfactants, used cleaning contact lenses and maintaining ocular tissue cell membrane integrity when wearing contact lenses; antiseptics |
| 05/29/2008 | US20080125493 Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia |
| 05/29/2008 | US20080125492 Medicaments Containing Panthenol |
| 05/29/2008 | US20080125491 screening for neuroprotectants such as -Isobutyryl-1,4-a-dimethyl-1,2,3,4,4a,9,10,10a-octahydro-phenanthrene-1-carboxylic acid amide, used for the prevention of neurodegenerative diseases and cardiovascular disorders |
| 05/29/2008 | US20080125490 the use of eicosapentaenoic acid or docosahexaenoic acid, in combination with other drugs, for treating cardiovascular disorders in patients suffering from urogenital disorders; preventing or treating underlying risk factors such as hypertension, dyslipidemia, obesity and diabetes |
| 05/29/2008 | US20080125489 administering retinoic acid receptor (RAR) agonists, that promote the formation of alveolar membranes and increase gas-exchange surface in the lungs; repsiratory system disorders |
| 05/29/2008 | US20080125488 Lactate Containing Pharmaceutical Composition and Uses Thereof |
| 05/29/2008 | US20080125486 sultosilic acid, 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid, used for improving the efficacy of chemotherapy, radiotherapy and/or cancer immunotherapy |
| 05/29/2008 | US20080125485 2-(acetyloxy)-5-hydroxybenzenesulfonic acid, or 5-(acetyloxy)-2-hydroxybenzene-sulfonic acid, or 2,5-bis(acetyloxy)benzenesulfonic acid; skin disorders like skin wrinkles, actinic keratosis, skin pigmentation and hyperpigmentation, hirsutism and hypertricosis, obesity due to adipogenesis |
| 05/29/2008 | US20080125484 Synthetic Lactone Formulations and Methods of Use |
| 05/29/2008 | US20080125483 3-Aminomethyl-5-methyl-hexanoic acid 1-ethyloxycarbonyloxy-ethyl ester; epilepsy, depression, anxiety, psychosis, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, panic, pain |
| 05/29/2008 | US20080125482 Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same |
| 05/29/2008 | US20080125481 Isoflavone metabolites |
| 05/29/2008 | US20080125479 Use in inhibiting PI-3-kinase activity in mammals; cancer; Acetic acid 4-diallylaminomethylene-6-hydroxy-1- alpha -methoxymeth-yl-10 beta ,13 beta -dimethyl-3,7,17-trioxo-1,3,4,7,10,11 beta , 12,13,14 alpha ,15,16,17-dodecahydro-2-oxa-cyclopenta[ alpha ]phenanthren-11-yl ester |
| 05/29/2008 | US20080125478 Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety |
| 05/29/2008 | US20080125477 7-(acryloyl) indole compositions and methods of making and using same |
| 05/29/2008 | US20080125476 Amorphous and crystalline forms; nonselective beta -adrenergic blocker with alpha 1-blocking activity; greater aqueous solubility and chemical stability |
| 05/29/2008 | US20080125475 Mixed ORL1/mu-agonists for the treatment of pain |
| 05/29/2008 | US20080125474 Pyrazole Analogs |
| 05/29/2008 | US20080125472 Use of an inhibitor of the renin-angiotensin system; candesartan, candesartan cilexetil, losartan, valsartan, irbesartan, tasosartan, telmisartan, and eprosartan |
| 05/29/2008 | US20080125471 Water-Soluble Tetrazolium Salts |
| 05/29/2008 | US20080125470 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-5-(2-(methylamino)-1,3-thiazol-4-yl)isoxazole-3-carboximidamide; cancer, viral infections, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disease |
| 05/29/2008 | US20080125469 Thiadiazole compounds and methods of use thereof |
| 05/29/2008 | US20080125468 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses |
| 05/29/2008 | US20080125467 (4-methylthiazol-2-yl)methyl 9-hydroxy-8-isobutyl-14-isopropyl-11,18-dimethyl-2,6,12,15-tetraoxo-3,7,13,16-tetraazanonadecan-5-ylcarbamate; Alzheimer's disease |
| 05/29/2008 | US20080125466 Useful in the treatment of conditions associated with pathological receptor activation; inhibiting binding of vanilloid ligand to a capsaicin receptor; (4-tert-Butyl-phenyl)-[1,1-dioxo-6-(3-trifluoromethyl-pyridin-2-yl)-1H-1?6-benzo[d]isothiazol-3-yl]-amine |
| 05/29/2008 | US20080125465 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 05/29/2008 | US20080125464 Prucalopride n-oxide |
| 05/29/2008 | US20080125463 2-Bromo-N-[1-(7-chloro-quinolin-4-yl)-piperidin-4-yl]-benzamide; fertility disorders, menstrual pains, endometriosis, pain, cancer, osteoporosis |
| 05/29/2008 | US20080125462 Cinnamate Salts Of A Beta-2 Adrenergic Agonist |
| 05/29/2008 | US20080125461 Treating, preventing and managing various pulmonary diseases or disorders; with a leukotriene inhibitor such as zafirlukast, montelukast |
| 05/29/2008 | US20080125460 inducible nitric oxide synthase inhibitors; acute or chronic inflammatory diseases of of peripheral organs and the central nervous system; 6-pyridinyl imidazo-[4,5-b]pyridine compounds; 2-[2-(4-Methoxypyridin-2-yl)ethyl]-6-(pyridin-4-yl)-3H-imidazo-[4,5-b]pyridine |
| 05/29/2008 | US20080125459 N-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof |
| 05/29/2008 | US20080125458 Pradofloxacin trihydrate; thermodynamically stable and is not converted to other crystal forms even during prolonged storage; non-hygroscopic |
| 05/29/2008 | US20080125457 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 05/29/2008 | US20080125456 macrogol 15 hydroxystearate as a surfactant and ethanol nonaqueous solvent; less toxicity and better stability during long-term storage; without precipitation of the drug when diluted with saline or dextrose solution |
| 05/29/2008 | US20080125455 disorders of the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus; sleep apnea; (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine and (S)-1-[1-(1,2,3,6,7,8-hexahydrocyclopent[g]indolyl)]-2-propylamine |
| 05/29/2008 | US20080125454 Methods and Compositions for Treatment of Scleritis and Related Disorders |
| 05/29/2008 | US20080125453 Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions |
| 05/29/2008 | US20080125452 Indolopyridines,Benzofuranopyridines and Benzothienopyridines |
| 05/29/2008 | US20080125451 Vinorelbine derivatives |
| 05/29/2008 | US20080125450 Pharmaceutical Compositions Comprising A Camptothecin Derivate |
| 05/29/2008 | US20080125449 hypotensive agent; cardiovascular disease; 5-ethoxycarbonyl-4-(2-ethoxy-6-pentadecylphenyl)-6-methyl-3,4 -dihydropyrimidin-2(1H)-one; |
| 05/29/2008 | US20080125448 Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety |
| 05/29/2008 | US20080125447 Combination Therapy |
| 05/29/2008 | US20080125446 For example, 6-amino-2-(chloro or fluoro)-8-(arylthio(oxo))-9H-purines; complex with Heat Shock Protein 90 (HSP 90); proliferative disorders such as breast cancer |
| 05/29/2008 | US20080125444 Acyclic oximyl hepatitis c protease inhibitors |
| 05/29/2008 | US20080125443 nonanalgesic, nonpeptide; for combating ischemic damage and/or effectuating ischemic preconditioning; preservative solution for organ transplants; 4-{(2R,5S)-4-[(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl]-2,5-d- imethyl-1-piperazinylmethyl} benzoic acid |
| 05/29/2008 | US20080125442 Cathepsin K Inhibitors and Atherosclerosis |
| 05/29/2008 | US20080125441 Spiro and dispiro 1,2,4-trioxolane antimalarials |
| 05/29/2008 | US20080125440 Tyrosine kinase inhibitors containing a zinc binding moiety |
| 05/29/2008 | US20080125439 Diazaindole-dicarbonyl-piperazinyl antiviral agents |
| 05/29/2008 | US20080125438 2-aminothiophene derivatives; {2-Amino-4-[(4-phenylpiperazin-1-yl)methyl]thiophen-3-yl}(4-chlorophenyl)methanone; analgesic for chronic neuropathic pain, cardiac disarrhythmias, angina; neurological disease or injury, sleep disorder, epilepsy, antidepressants |
| 05/29/2008 | US20080125437 Mapk/erk kinase inhibitors |
| 05/29/2008 | US20080125436 MgluR5 modulators |
| 05/29/2008 | US20080125435 E. g., 1-(3-chloro-phenyl)-3-[1-(7-chloro-quinolin-4-yl)-piperidin-4-yl]-thiourea; regulation of ovulation, modulation of prostaglandin E2 receptors; fertilization, nidation, decidualization (e.g. placenta formation) and menstruation; hypermenorrhea, dysmenorrhea; endometriosis; anticarcinogenic agents |
| 05/29/2008 | US20080125434 E. g., 6-(4-benzooxazol-2-yl-piperazin-1-yl)pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide; diseases such as related to dyslipidemia and metabolism disorders of lipid; especially diseases related to elevated lipid levels, cardiovascular disease, antidiabetic agents; obesity; anticholesterol agent |
| 05/29/2008 | US20080125433 Method of treating hair loss using thyromimetic compounds |
| 05/29/2008 | US20080125432 E.g., 2-(4-fluoro-phenylamino)-4-methyl-thiazole-5-carboxylic acid ((S)-1-naphthalen-2-yl-ethyl)-amide; blockingion channels of the Ky1, the Ky3, and the Ky1.5 subfamilies; nervous system disorders; cardiotonic agents; antiepileptic agents; anxiolytic agents; multiple sclerosis; Alzheimer's diseasse |
| 05/29/2008 | US20080125431 E.g., 3-(2'-Morpholin-4-ylmethyl-biphenyl-4-ylmethyl)-1-oxa-3-aza-spiro[4.5]decan-2-one; acute and chronic neurological and psychiatric disorders and chronic and acute pain disorders; Alzheimer's disease; schizophrenia; antidepressants; bipolar disorders; antiischemic agents; cardiotonic agents |
| 05/29/2008 | US20080125430 New small molecule inhibitors of mdm2 and the uses thereof |
| 05/29/2008 | US20080125429 1-{[5-[4-(Methylsulfonyl)phenoxy]-2-(2-pyridinyl)-1H-benzimidazol-6-yl]methyl}-5-thioxo-2-pyrrolidinone;glucokinase activator; antidiabetic agents; obesity; prevention of retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis; antiischemic agents; cardiotonic agents |
| 05/29/2008 | US20080125428 Administering N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate (lapatinib) with another inhibitor of epidermal growth factor receptor tyrosine kinase and/or erbB-2 (gefitinib, erlotinib); breast cancer |
| 05/29/2008 | US20080125427 Novel Inhibitors of Rho-Kinases |
| 05/29/2008 | US20080125426 7-(4-Chlorophenyl)-4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile; reversible inhibitors of cysteine proteases S, K, F, L, B; diseases associated with Cathepsin S; antiinflammatory agent, autoimmune diseases; asthma, rheumatoid arthritis, multiple sclerosis, Alzheimer's and Crohn's disease |
| 05/29/2008 | US20080125425 Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors |
| 05/29/2008 | US20080125424 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| 05/29/2008 | US20080125423 N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide as an enzyme inhibitor for both Fab I and Fab K which are used in the biosynthesis of fatty acids; enoyl-acyl-carrier protein renamed Fab 1; bactericides; fungicides; Staphylococcus aureus; antibiotics |
| 05/29/2008 | US20080125422 Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions |
| 05/29/2008 | US20080125419 Benzothiazole derivatives with activity as adenosine receptor ligands |